Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 8:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 33,041 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder (MDD)
Interventions
CTC-501
Drug
Lead sponsor
Chase Therapeutics Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Long Beach, California
Conditions
Anxiety Disorders, Somatoform Disorders
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Conditions
Long QT Syndrome
Interventions
LQT-1213, Placebo, Dofetilide 250 μg Cap
Drug
Lead sponsor
Thryv Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain
Interventions
Botulinum toxin type A, 0.9% Sodium Chloride Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-06882961
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
42
States / cities
Harbor City, California • Long Beach, California • Los Angeles, California + 33 more
Conditions
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions
Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging and Dose Frequency of LIPO-102

NCT00918814
Conditions
Subcutaneous Adipose Tissue Reduction
Interventions
LIPO-102, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Completed Not applicable Interventional Results available

Low Dose Naltrexone (LDN) Immune Monitoring

NCT02107014
Conditions
Fibromyalgia
Interventions
Low Dose Naltrexone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
Imvotamab, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more
Conditions
Postbariatric Hypoglycemia
Interventions
MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C)
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Healthy Volunteers
Interventions
BGB-3111, Placebo, Moxifloxacin
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Conditions
Hypertriglyceridemia
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neuralgia, Postherpetic
Interventions
Gabapentin extended-release tablets
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Conditions
Type 2 Diabetes Mellitus
Interventions
TTP054, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
19
States / cities
Chula Vista, California • Los Angeles, California • Denver, Colorado + 15 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

NCT00122447
Conditions
Impaired Glucose Tolerance, Prediabetic State
Interventions
Aspirin, Alpha lipoic acid, Olmesartan, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
Conditions
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
Interventions
RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4, Control Vaccine 2, Placebo, Control Vaccine 1
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
50
States / cities
Gadsden, Alabama • Vestavia Hills, Alabama • Huntington Beach, California + 43 more
Conditions
Influenza Immunization
Interventions
Pandemic flu H5 mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
Conditions
Postoperative Pain
Interventions
HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
Conditions
Pulmonary Arterial Hypertension
Interventions
L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
Drug · Device · Other
Lead sponsor
Pharmosa Biopharm Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Conditions
Healthy Volunteers
Interventions
Placebo, Fludrocortisone, Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Completed Not applicable Interventional Accepts healthy volunteers

Astaxanthin Reduces Exercising Heart Rate.

NCT05282355
Conditions
Metabolic Flexibility
Interventions
Astaxanthin, Placebo
Dietary Supplement
Lead sponsor
University of North Alabama
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Florence, Alabama
Conditions
Hypogammaglobulinemia, Lung Transplantation
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York